Search - tctmd.com

Displaying 621 - 637 of 637

Sort: Relevancy | Date

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

Michael O'Riordan

September 22, 2016

News Daily News

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Michael O'Riordan

September 16, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

Depression Increases Risk of Acute MI by 30% in HIV-Positive Patients

L.A. McKeown

August 25, 2016

News Daily News

Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook

L.A. McKeown

August 04, 2016

News Daily News

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

L.A. McKeown

July 28, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Protein-Based Risk Score Shows Potential for Tailored Medicine in Cardiology

Yael L. Maxwell

June 24, 2016

News Daily News

USPSTF 收紧一级预防的建议，称阿司匹林应只在高危人群中使用

Michael O'Riordan

April 12, 2016

News Daily News

USPSTF Tightens Up Primary-Prevention Recommendations, Saying Aspirin Should Be Used Only in High-Risk Individuals

Michael O'Riordan

April 12, 2016

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Industry News

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

September 08, 2015

Advertisement

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Depression Increases Risk of Acute MI by 30% in HIV-Positive Patients

Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Protein-Based Risk Score Shows Potential for Tailored Medicine in Cardiology

USPSTF 收紧一级预防的建议，称阿司匹林应只在高危人群中使用

USPSTF Tightens Up Primary-Prevention Recommendations, Saying Aspirin Should Be Used Only in High-Risk Individuals

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content